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Summary Plasma samples were collected from 20 patients undergoing phase I clinical trial with flavone-8-
acetic acid (FAA; 4.8 g m-2 per dose) in combination with recombinant human interleukin-2 (rhIL-2;
6-18 i.u. m-2 per day) for the treatment ofmetastatic melanoma. Samples were analysed for nitrate content as
an indication of the oxidation of L-arginine to nitric oxide. Pretreatment plasma nitrate levels (53 ± 4 JIM)
were significantly above those of healthy volunteers (19 ± 4 JiM). The maximum plasma nitrate concentration
obtained after treatment, 190 ± 29 jiM (range 49 to 655 JiM), was comparable to that of mice treated with
FAA. Most of the increases occurred 3-5 days after initiation of a 5 day infusion of rhIL-2, but three of the
increases occurred within 2 days of a 1 h infusion of FAA alone. The maximum plasma nitrate concentrations
of the three patients which underwent remission (two complete, one partial) following treatment
(368 ± 143 JiM) were significantly higher (P<0.05) than those of patients with progressive disease. Hypoten-
sion was the major dose-limiting side effect, and there was no relationship between the degree of hypotension
and the rise in plasma nitrate. The results provide evidence that treatment of patients with FAA and rhIL-2
induce the synthesis of nitric oxide, a physiological mediator and potential cytotoxic agent.
Flavone-8-acetic acid (FAA), a synthetic flavonoid (Atassi et
al., 1985), has shown outstanding activity against murine
experimental solid tumours (Plowman et al., 1986; O'Dwyer
et al., 1987). This activity is augmented in some tumours by
co-administration of interleukin-2 (IL-2) (Wiltrout et al.,
1988). However, clinical trials of FAA, administered either as
a single agent or in combination with IL-2 (Kaye et al.,
1990), have so far not shown evidence of activity, raising the
question of whether the action of FAA is species specific.
One method of resolving this question is to determine wheth-
er any of the biological responses induced by FAA in mice
can be detected in humans.
Studies in our laboratory have provided evidence that
FAA stimulates L-arginine-dependent nitric oxide production
in vitro by activated murine macrophages (Thomsen et al.,
1990). Enhanced nitrate concentration in plasma is largely
due to increased biosynthesis of nitric oxide via the L-
arginine-dependent pathway (Leaf et al., 1990). Our finding
of increased plasma nitrate concentrations in the plasma of
normal and tumour-bearing mice following FAA administra-
tion indicated that this compound also stimulated nitric
oxide production in vivo (Thomsen et al., 1991). Moreover,
for a series of xanthenone-4-acetic acid (XAA) analogues of
FAA, the measured increase in plasma nitrate concentration
was related to the tumour growth delay, suggesting that
nitric oxide production was correlated in some way with the
antitumour effects of FAA. Since plasma nitrate concentra-
tions are simple to measure, it is of interest to determine
whether such a response is evident in patients.
In this study, we have measured nitrate concentration in
plasma samples from a series of 20 patients with metastatic
malignant melanoma, taken before and after treatment with
a combination of FAA and IL-2, details of which will be
reported in a future article (O'Reilly et al., unpublished).
Three of these patients have responded to this treatment,
allowing a comparison of plasma nitrate levels between re-
sponders and nonresponders.
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Materials and methods
Clinical methods
Twenty patients with metastatic melanoma were entered into
a phase I clinical trial of FAA (Lipha Lyonnaise Industrielle,
Lyons, France) combined with rhIL-2 (Proleukin, Eurocetus,
Amsterdam, Netherlands). Prior to treatment, all patients
had progressive disease and a performance status <3 on a
5-grade scale according to WHO criteria (Miller et al.,
1981).
The treatment protocol, which had been approved by the
local ethical committee on human experimentation, was
modified during the trial to reduce the severity of side effects
(i.e. hypotension). Thus, for patients 1-8, FAA (4.8 gm2)
was given as a 1 h infusion in 500 ml 0.9% saline without
urine alkalinisation on days 1, 8, and 15. rIL-2 (6-18 x 106
international units/m2/day) was given as a continuous
infusion on days 8-12 and 15-19. For patients 9-20, FAA
and rhIL-2 were given as described except that rIL-2 was
given on days 8-12 only.
Following treatment, patients were assessed for clinical
responses according to standard WHO criteria (Miller et al.,
1981). Each patient received a second course of treatment
after 2 weeks unless a complete response to treatment or
evidence of disease progression was observed.
Plasma samplesfor nitrate analyses
Blood samples, taken before and at intervals after FAA and
rIL-2 administration, were collected into lithium heparin
tubes. After centrifugation plasma was removed and
immediately frozen at -20'C. Samples were transported
between the UK and New Zealand after filter-sterilisation
using cellulose acetate filters. Plasma samples were also
obtained in New Zealand from blood donated by six healthy
volunteers. Control experiments, in which the latter samples
were stored at room temperature for up to 10 days, showed
that these storage conditions did not significantly change
nitrate concentrations.
Plasma nitrate levels were determined as previously des-
cribed (Thomsen et al., 1991). After precipitation of plasma
proteins with 30% ZnSO4 and reduction of nitrate in the
supernatant to nitrite using acid-washed cadmium powder,
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nitrite was measured using a microplate assay based on the
Griess reaction (Green et al., 1982). Plasma nitrate concent-
rations were expressed as the mean ± s.e.m. (standard error
of the mean) for groups of data. Student's t-test was used to
compare plasma nitrate concentrations between groups.
Values for P<0.05 were considered significantly different.
Monitoring ofbloodpressure
Systolic and diastolic blood pressure levels were recorded at
the same time as blood samples were collected from each
patient during treatment.
Results
For the 20 patients entered in the trial, pretreatment concent-
rations of nitrate in plasma prior to administration of FAA
and rIL-2 were significantly higher than concentrations in
plasma from healthy volunteers (P<0.05) (Table I). Plasma
nitrate concentrations increased during treatment (Figure 1)
with maximal concentrations observed for the patient group
significantly higher than the pretreatment values (P<0.05)
(Table I).
Increases were most commonly observed during or follow-
ing rIL-2 infusion, although a substantial increase was also
observed for three patients after infusion of FAA alone.
Patient one showed an increase from a pretreatment level of
40 JAM to 655 JAM at 18 h after the first infusion of FAA
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during the first treatment course; patient 10 showed an in-
crease from 70JAM to 323 jAM at 24 h after the third infusion
of FAA in the second treatment course; patient 17 showed an
increase from 82JAM to 195 JAM at 24 h after the first infusion
of FAA during the second treatment course (Figure 1).
Three of the 20 patients responded to the treatment
regime. Patients one and two showed complete responses and
patient 11 showed a partial response. Maximal plasma nitrate
concentrations were significantly greater for these three
patients compared with the 17 patients with progressive
disease following treatment (P<0.05) (Table II). A drop of
systolic blood pressure of >30 mmHg which required intra-
venous fluid therapy occurred after 22 of 97 infusions of
FAA. There was no relationship between plasma nitrate
levels and blood pressure.
Table I Plasma nitrate concentrations (mean ± s.e.m.) in healthy
volunteers and cancer patients before and after treatment
Plasma nitrate
Group (AM)
Healthy volunteers 19 ± 4a
Cancer patients - before treatment 53 ± 4
Cancer patients - after treatmentb 190 ± 29a
ap<0.05 compared with patients' pretreatment value; bMaximal
concentration obtained from plasma samples analysed for each
patient.
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Figure 1 Plasma nitrate concentrations for patients before and during treatment with FAA in combination with rIL-2. 0 and A
are the first and second courses of treatment respectively.
Table II A comparison between plamsa nitrate concentrations
observed for patients showing a clinical response to treatment (n = 3)
and those with progressive disease after treatment (n = 17). Plasma
nitrate levels are the maximal concentrations (mean ± s.e.m.) for
each patient group
Plasma nitrate
Cancer patients (fLM)
Progressive disease 158 ± 18
Clinical response 368 ± 143a
ap<0.05 compared with progressive disease.
Discussion
The present study appears to be the first to document in-
creased plasma nitrate levels in humans in response to a
clinical treatment protocol incorporating FAA and IL-2,
although an plasma nitrate increases following administra-
tion of IL-2 alone have been reported recelty (Hibbs et al.,
1992). In 15 of the 20 patients studied here, there was at least
a doubling of the pretreatment plasma nitrate concentration.
The maximum plasma nitrate concentrations obtained after
treatment ranged from 49 to 655 jLM (mean 190 SAM). This
compares with the maximum plasma nitrate concentrations
12 h after a therapeutic dose of FAA of 85 jLM (non tumour-
bearing mice) and 630 gM (colon 38 tumour-bearing mice)
(Thomsen et al., 1991). Most of the increases in plasma
nitrate concentration in patients was observed 3-5 days after
commencement of infusion of IL-2, suggesting that IL-2 may
be an important stimulator of nitric oxide production in
humans treated with FAA and IL-2 combination therapy.
Clinical studies show that IL-2 induces increased serum con-
centrations of the cytokines TNF-a and IFN-' (Gemlo et al.,
1988; Blay et al., 1990; Boccoli et al., 1990). These cytokines
are known to induce nitric oxide synthesis in both mac-
rophages and endothelial cells in experimental systems (Kil-
bourn & Belloni, 1990). Increases in plasma nitrate may thus
be mediated by an IL-2-induced cytokine cascade.
Twelve of the patients in this study also had plasma levels
of TNF, GM-CSF, and IL-6 measured (Haworth et al.,
unpublished). Interestingly a very marked rise in all these
cytokines was noted 2-8 h after a course of FAA, but only
when the FAA was given 2-4 days after infusion of IL-2.
The highest nitrate level was found at a similar time point in
11 of the 14 patients who had nitrate measured at that time.
Substantial increases in plasma nitrate levels were observed
in three patients within 2 days of infusion of FAA alone,
suggesting that stimulation of nitric oxide production is not
exclusively dependent on infusion of IL-2. In mice, FAA
stimulates increases in plasma nitrate over a period of 12 h
(Thomsen et al., 1991), and induces increased serum concen-
trations of the cytokines TNF-a and IFN-'y (Urba et al.,
1988; Mace et al., 1990) suggesting that nitric oxide produc-
tion may be induced either directly by FAA or indirectly
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through the induction of cytokines. It is therefore possible
that, in these three patients, FAA is having a biological effect
similar to that found in mice. Since the number of plasma
samples studied was small, further studies are required to
provide a definitive answer to whether FAA elevates plasma
nitrate in a clinical situation. In particular, analysis ofplasma
samples taken 2-7 days after infusion of FAA alone, which
were not available from this study, may help to clarify the
effect of FAA on nitric oxide production.
Pretreatment nitrate levels (53 ± 4gM) were found to be
significantly above those of healthy volunteers (19 ± 4 SAM). It
is possible that this is a consequence of increased nitric oxide
synthesis in response to higher basal production of cytokines
in some cancer patients. Plasma TNF concentrations have
been shown on average to be higher in cancer patients than
in control patients (Balkwill et al., 1987).
Hypotension was the dose-limiting side-effect of the com-
bination therapy of FAA with IL-2, as it is with TNF
(Creaven et al., 1989) and endotoxin (Engelhardt et al.,
1991). Kilbourn et al., 1990 and Thiemermann & Vane, 1990
have shown that nitric oxide is involved in the induction of
hypotension by TNF and endotoxin in animals. We have not
been able to measure blood pressure in mice treated with
FAA, although the transient rise in haemoglobin concentra-
tion observed in mice treated with FAA (Ching et al., 1991)
is consistent with a drop in blood pressure. Studies of the
relationship between blood pressure and plasma nitrate levels
in mice would allow a clearer interspecies comparison of the
effects of FAA and IL-2.
Despite the fact that nitric oxide is known to regulate
blood pressure in humans, no correlation was found between
plasma nitrate levels and blood pressure in patients treated
with this clinical regime. A possible explanation is that the
major source of nitrate in plasma is from sources other than
the endothelial cells controlling blood pressure. Alternatively,
the effect of nitric oxide on blood pressure may be counter-
balanced by the release of other substances such as
endothelin (Clarke et al., 1989), thereby obscuring the simple
relationship between nitric oxide production reflected as nit-
rate in plasma and hypotension.
The number of patients responding to treatment in this
study (3 of 20) is too small to provide adequate statistical
evaluation of the relationship between the maximum
measured plasma nitrate concentration and the response rate.
Nevertheless, the finding of a significant difference in nitrate
concentrations between responders and non-responders
(P<0.05) suggests that further analysis should be carried
out. In mice it has been suggested, on the basis of the
correlation between nitric oxide production and antitumour
activity of FAA analogues, that nitric oxide production con-
tributes to the antitumour effect of FAA (Thomsen et al.,
1990; 1991). Nitric oxide may have a cytostatic and cytotoxic
role as a consequence of its ability to bind to and inhibit the
active iron-sulphur centres of key enzymes in ATP and DNA
synthesis (Lancaster & Hibbs, 1990).
The lack of effect of FAA alone on plasma nitrate levels,
which was observed in the majority of patients, suggests that
its failure as a clinical antitumour agent may be a lack of
dose potency of this agent in stimulating nitric oxide produc-
tion in human systems. Other agents which stimulate the
nitric oxide synthesis pathway, such as TNF-oa (Creaven et
al., 1989) and endotoxin (Engelhardt et al., 1991), are cur-
rently being investigated as potential clinical antitumour
agents. 5,6-Dimethyl XAA, a more dose-potent analogue of
FAA which is a powerful inducer of nitric oxide both in vitro
(Thomsen et al., 1990) and in vivo (Thomsen et al., 1991), is
currently under consideration as a candidate for clinical trial.
Studies of the relationship between plasma nitrate concentra-
tion and clinical response to these agents may be pivotal in
establishing the direction of future investigations of host-
mediated therapies. Development of more potent agents in
stimulation of nitric oxide production in human systems may
need to be emphasised, with nitrate analysis providing a
useful predictive test for a clinical response to such
treatments.
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